Sen. Chuck Grassley warned the administration not to back off from a proposed rule that would create a website to disclose medical researchers’ conflicts of interest. “I am troubled that taxpayers cannot learn about the outside income of the researchers whom the taxpayers are funding, and this flies in the face of President Obama’s call for more transparency in the government. The public’s business should be public.
Despite promises to cut back on Pharma funds, 56% of DSM V panel members have reported industry ties— Zero improvement over the percent of DSM-IV members.
Bernard Carroll, former head of psychiatry at Duke University and once Charles Nemeroff’s boss, said parts of Nemeroff’s work involved Paxil, a GlaxoSmithKline antidepressant. “Basically, he was doing basic science pimping for Paxil to produce talking points,” Carroll told The Herald in an e-mail Thursday. “All he ever produced was speculation but that was enough to satisfy Glaxo marketing. . . . I have been exposing his shenanigans for some years.”
Last year Nemeroff, as chair of the Department of Psychiatry at Emory University, was the intense focus of an investigation by Sen. Charles Grassley, R-Iowa, who said he was concerned about the money the psychiatrist received from drug companies while conducting supposedly unbiased research for the National Institutes of Health on drugs made by the companies he was receiving money from.
Charles Nemeroff, who failed to disclose to Emory University approximately $800,000 in payments he received from drug maker GlaxoSmithKline (GSK) while he was the principal investigator (PI) on a multi-million dollar grant from the NIH to study five GSK antidepressants, is leaving the university.